Will a new weight-loss drug mess with your coffee or antidepressants? a new study aims to find out.

NCT ID NCT06564441

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial looked at whether multiple doses of Survodutide, a weight-loss drug, change how the body absorbs and processes three common drugs: bupropion (an antidepressant), caffeine, and midazolam (a sedative). Thirty-four otherwise healthy adults with overweight or obesity took these drugs alone and then again while on Survodutide. Researchers measured drug levels in the blood to see if Survodutide interferes with them. The goal is to understand potential drug interactions for future safe use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Survodutide (also known as BI 456906), bupropion, caffeine, midazolam
What this could lead to
If successful, this study could help doctors understand whether Survodutide changes how other drugs work in the body, guiding safer use in people with overweight or obesity.
What could go wrong
This is an early Phase 1 trial with only 34 participants, so results may not apply to everyone. The study focuses on drug interactions, not on treating obesity or related conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • SGS Life Science Services - Clinical Research

    Edegem, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.